Level 2

Company Announcements

SHIRE PLC - Blocklisting - Interim Review

Related Companies

By PR Newswire

PR Newswire

London, May 23

BLOCK LISTING SIX MONTHLY RETURN

May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant: Shire plc
Name of scheme: Shire Sharesave Scheme
Period of return: From: November 23, 2016 To:  May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 184,611
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 17,079
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 167,532

   

Name of applicant: Shire plc
Name of scheme: Shire Portfolio Share Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 769,615
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 405,083
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 364,532

   

Name of applicant: Shire plc
Name of scheme: Shire Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 244,057
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 6,359
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 237,698

   

Name of applicant: Shire plc
Name of scheme: Shire Long Term Incentive Plan 2015
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 2,836,412
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 145,740
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 2,690,672

   

Name of applicant: Shire plc
Name of scheme: Shire Global Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 1,604,243
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 3,400
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 1,600,843


 

Name of applicant: Shire plc
Name of scheme: Baxalta Exchange Awards
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 20,488,204
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 2,492,337
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 17,995,867

   

Name of contact: Sarah Rixon, Company Secretarial Assistant
Telephone number of contact: 01256 894000

For further information please contact:

Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1-617 588 8607
Debbi Ford debbi.ford@shire.com  +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Top of Page